FERMAGATE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	CO3.2Fe.4Mg.12HO.4H2O
Molecular Weight	545.068
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.O.O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Fe+3].[Fe+3].[O-]C([O-])=O

InChI

InChIKey=VESOWWBEYMMDFG-UHFFFAOYSA-A

InChI=1S/CH2O3.2Fe.4Mg.16H2O/c2-1(3)4;;;;;;;;;;;;;;;;;;;;;;/h(H2,2,3,4);;;;;;;16*1H2/q;2*+3;4*+2;;;;;;;;;;;;;;;;/p-14

HIDE SMILES / InChI

Molecular Formula	Fe
Molecular Weight	55.845
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	CH2O3
Molecular Weight	62.0248
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Mg
Molecular Weight	24.305
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/mesh/67541219 | https://www.ncbi.nlm.nih.gov/pubmed/19158369 | http://www.opkorenal.com/pipeline/product_candidates.html

FERMAGATE is a phosphate binder with phosphate plasma levels lowering activity. It is in Phase 3 development in the US and in Europe for the treatment of hyperphosphatemia in dialysis patients. It is made up of magnesium and ferric iron atoms held in an insoluble, rigid, crystalline-layered structure, with carbonate groups lying between the layers. Upon oral administration, the carbonate ions in FERMAGATE are exchanged for free phosphate ions released from food in the gastrointestinal tract; thereby, strongly binding phosphate. This inhibits phosphate uptake and preventing hyperphosphatemia.

Originator

Approval Year

PubMed

Title	Date	PubMed
Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?	2015-04	25815172
Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.	2009-02	19158369
Different Mg to Fe ratios in the mixed metal MgFe hydroxy-carbonate compounds and the effect on phosphate binding compared with established phosphate binders.	2002-01	11782897

Sample Use Guides

In Vivo Use Guide

Recommended daily dose: 3000 mg, three pills per day.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:20:20 GMT 2025` Edited by `admin` on `Mon Mar 31 18:20:20 GMT 2025`
Record UNII	LH78JQC1MP
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DIIRON(III) TETRAMAGNESIUM CARBONATE DODECAHYDROXIDE-WATER (1/4)

Preferred Name

English

FERMAGATE

Official Name

English

IRON MAGNESIUM CARBONATE HYDROXIDE(FE2MG4(CO3)(OH)12) TETRAHYDRATE

Common Name

English

ALPHAREN

Brand Name

English

fermagate [INN]

Common Name

English

FERRATE (FE(OH)63-), (OC-6-11)-, MAGNESIUM CARBONATE (2:4:1), TETRAHYDRATE

Common Name

English

FERRATE (FE(OH)63-), (OC-6-11)-, MAGNESIUM CARBONATE, HYDRATE (2:4:1:4)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C78275